Proportion of Patients With Hematologic Overall Response (Partial Response [PR]+ Very Good PR [VGPR]+ Amyloid Complete Response [ACR]+ Stringent Complete Response [sCR]) After 3 Months (3 Cycles) of Therapy [clinicaltrials_resource:NCT01078454/outcome/1]
outcome [clinicaltrials_vocabulary:outcome]
Proportion of Patients With Hematologic Overall Response (Partial Response [PR]+ Very Good PR [VGPR]+ Amyloid Complete Response [ACR]+ Stringent Complete Response [sCR]) After 3 Months (3 Cycles) of Therapy [clinicaltrials_resource:NCT01078454/outcome/1]
Bio2RDF identifier
NCT01078454/outcome/1
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:NCT01078454/outcome/1
group [clinicaltrials_vocabulary:group]
measure [clinicaltrials_vocabulary:measure]
population [clinicaltrials_vocabulary:population]
All enrolled patients are included in this analysis.
safety issue [clinicaltrials_vocabulary:safety-issue]
time frame [clinicaltrials_vocabulary:time-frame]
Assessed at 3 months
type [clinicaltrials_vocabulary:type]
alternate
Proportion of Patients With He ...... 3 Months (3 Cycles) of Therapy
@en
identifier
clinicaltrials_resource:NCT01078454/outcome/1
title
sCR: ACR and no clonal cells i ...... involved FLC if only FLC measu
@en
type
label
Proportion of Patients With He ...... esource:NCT01078454/outcome/1]
@en